A randomized phase II chemoprevention study of iloprost versus placebo in patients at high risk for lung cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Iloprost (Primary)
- Indications Bronchopulmonary dysplasia; Lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 05 Apr 2011 Results presented at the 102nd Annual Meeting of the American Association for Cancer Research.
- 22 Dec 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.